Strategies to assess blood-brain barrier penetration (Q38090672)

28 August 2017

title

Strategies to assess blood-brain barrier penetration (English)

1 reference

28 August 2017

1 reference

Li Di

1

1 reference

28 August 2017

Edward H Kerns

series ordinal

2

1 reference

28 August 2017

Guy T Carter

series ordinal

3

1 reference

28 August 2017

language of work or name

English

0 references

publication date

1 June 2008

1 reference

Expert Opinion on Drug Discovery

28 August 2017

published in

1 reference

28 August 2017

volume

3

1 reference

28 August 2017

issue

6

1 reference

28 August 2017

page(s)

677-687

1 reference

Blood-brain barrier delivery

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.6.677

Can the pharmaceutical industry reduce attrition rates?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.6.677

Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.6.677

Strategies to advance translational research into brain barriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.6.677

The highly permeable blood-brain barrier: an evaluation of current opinions about brain uptake capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.6.677

High throughput artificial membrane permeability assay for blood-brain barrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.6.677

Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.6.677

Active targeting of brain tumors using nanocarriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.6.677

Blood-brain barrier delivery of protein and non-viral gene therapeutics with molecular Trojan horses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.6.677

shRNA and siRNA delivery to the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.6.677

CSF as a surrogate for assessing CNS exposure: an industrial perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.6.677

Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.6.677

Pharmacokinetics and pharmacodynamics of seven opioids in P-glycoprotein-competent mice: assessment of unbound brain EC50,u and correlation of in vitro, preclinical, and clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.6.677

Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.6.677

Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.6.677

Development of a computational approach to predict blood-brain barrier permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.6.677

Challenges for blood-brain barrier (BBB) screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.6.677

The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.6.677

Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.6.677

Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.6.677

AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.6.677

In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.6.677

Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.6.677

Evaluation of in vitro brain penetration: optimized PAMPA and MDCKII-MDR1 assay comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.6.677

In vitro models for the blood-brain barrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.6.677

Flavonoid permeability across an in situ model of the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.6.677

Fluvastatin stabilizes the blood-brain barrier in vitro by nitric oxide-dependent dephosphorylation of myosin light chains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.6.677

Modelling of the blood-brain barrier in drug discovery and development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.6.677

Comparison of in vitro BBMEC permeability and in vivo CNS uptake by microdialysis sampling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.6.677

Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.6.677

Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.6.677

Progress in brain penetration evaluation in drug discovery and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.6.677

Comparison of species differences of P-glycoproteins in beagle dog, rhesus monkey, and human using Atpase activity assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.6.677

In silico predictions of blood-brain barrier penetration: considerations to "keep in mind".

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.6.677

Predicting P-glycoprotein substrates by a quantitative structure-activity relationship model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.6.677

Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.6.677

In silico prediction of blood–brain barrier permeation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.6.677

Classification analysis of P-glycoprotein substrate specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.6.677

Log(BB), PS products and in silico models of drug brain penetration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.6.677

21 January 2018

Identifiers

DOI

10.1517/17460441.3.6.677

1 reference

28 August 2017

1 reference